Hypoxia inducible BHLHB2 is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma

Detection of Hypoxia With 18F-Fluoromisonidazole (18F-FMISO) PET/CT in Suspected or Proven Pancreatic Cancer

“…Despite the evidence that pancreatic carcinoma displays features of hypoxia, 10,15,16 our results indicate that only 2 of 10 pancreatic tumors (2 of 7 pancreatic adenocarcinomas) appeared to demonstrate any visualized detectable 18 F-FMISO activity and the 18 F-FMISO activity in these 2 tumors was only mildly greater than background pancreatic activity. The uptake in the positive tumors would be regarded as grade 2 (focal uptake mildly greater than background) using a qualitative scale suggested by Hicks et al 17 In contrast, all tumors were metabolically active with 18 F-FDG PET/CT imaging.…”

Definition of a serum marker panel for glioblastoma discrimination and identification of Interleukin 1β in the microglial secretome as a novel mediator of endothelial cell survival induced by C-reactive protein

“…Moreover it could distinguish invasive type of breast cancer and serves as potential classification marker in case renal cell carcinomas [48]. BHE40 protein expression has been demonstrated as an independent prognostic marker in case of pancreatic ductal adenocarcinoma [49]. However, to our knowledge, there are no reports about the serum levels of BHE40 correlating to any type of cancer.…”

Overexpression of the DEC1 Protein Induces Senescence In Vitro and Is Related to Better Survival in Esophageal Squamous Cell Carcinoma

“…We scored DEC1 with the criteria that combined the rate of nuclear positive cells with intensity because the intensity of the protein was not uniform among different lesions [34]. The rate of positive cells was grade: 0, <5%; 1, 5∼25%; 2, 26∼50%; 3, 51∼75%; 4, >75%.…”

“…It is wildly used as a marker of senescence in vivo , and it could directly induce senescence in cultured cells [25], [26], [27]. DEC1 is wildly expressed in most normal human tissues, but only in a proportion of cells, while in tumors, expression of DEC1 is thought to be induced by hypoxia and was detected up-regulated in several kinds of malignancies, including breast, stomach, colon, lung, liver, and pancreatic ductal adenocarcinoma [28], [29], [30], [31], [32], [33], [34]. However, DEC1 expression in ESCC has not been investigated yet, and could DEC1 play the same role in ESCC as in above-mentioned cancers?…”